HighTower Advisors LLC Buys 244 Shares of Haemonetics Co. (NYSE:HAE)

HighTower Advisors LLC raised its position in shares of Haemonetics Co. (NYSE:HAE) by 7.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,353 shares of the medical instruments supplier’s stock after purchasing an additional 244 shares during the period. HighTower Advisors LLC’s holdings in Haemonetics were worth $262,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 240 shares during the period. AlphaQuest LLC increased its stake in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after purchasing an additional 1,826 shares in the last quarter. KBC Group NV raised its position in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 712 shares during the period. iSAM Funds UK Ltd purchased a new stake in shares of Haemonetics during the 3rd quarter valued at approximately $204,000. Finally, Ashton Thomas Private Wealth LLC bought a new position in Haemonetics in the 4th quarter worth approximately $284,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Price Performance

HAE stock opened at $64.09 on Thursday. The firm has a 50 day simple moving average of $65.42 and a two-hundred day simple moving average of $74.47. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The stock has a market cap of $3.22 billion, a PE ratio of 25.23, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a one year low of $58.80 and a one year high of $97.97.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, analysts predict that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HAE. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. started coverage on Haemonetics in a research note on Friday, December 6th. They set an “overweight” rating and a $116.00 price objective on the stock. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. JMP Securities decreased their price target on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research report on Friday, February 7th. Finally, Needham & Company LLC cut their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.